Trump's Pharma Agreements Raise Questions on Drug Cost Control
By Editor • September 2, 2026 • 1 min read
The White House's announcement of new drug pricing agreements with mid-sized biotech firms has sparked interest as President Trump aims to leverage the issue for the upcoming midterm elections.
However, experts caution that these voluntary agreements may have limited immediate impact, as they primarily affect Medicaid, which already benefits from the lowest prices, while leaving Medicare untouched.
Source: www.statnews.com
